Sanofi-Aventis
Tokyo, Japan
NCT Number: NCT00459004
The primary objective is to verify the dose-response relationship of rimonabant on body weight change.
The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body weight loss and on secondary criteria associated with comorbidities, and to evaluate the safety and the pharmacokinetics of SR141716.
Looking for future studies?
Notify Me20 year–70 year
All sexes
Interventional
Phase 2
Tokyo, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Looking for future studies?
Notify MeSanofi
Industry
A Dose-Response Relationship Study of SR141716 in Obese Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04014296
Body Weight, Body Weight Changes
Birmingham, Alabama, United States
View Trial DetailsNCT00687115
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT05231824
Body Weight, Body Weight Changes
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06945419
Body Weight, Body Weight Changes
Daytona Beach, Florida, United States
View Trial Details